Seroxat is also known as Paxil and Aropax. Blog exposes Bob Fiddaman Human rights abuser who won two SCIENTOLOGY CCHR (human rights!) awards.
blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1
This blog is brougt to you consistent with subsection 3 of the Protection from Harassment Act - i.e. blogs created to prevent or detect a crime http://www.opsi.gov.uk/acts/acts1997/ukpga_19970040_en_1
Sunday, 17 October 2010
Mark Harvey's group calimed 10,000 yet served 314 Seroxat writs - who keeps the public funded legal aid?
http://209.85.229.132/search?q=cache:HVY-Qp_p-YAJ:www.fiercepharma.com/story/uk-patients-sue-paxil-withdrawal/2008-01-09+harvey+seroxat&cd=14&hl=en&ct=clnk
. It was the first antidepressant to be slapped with a suicide-risk warning. It's drawn fire--and lawsuits--from U.S. patients who say they went into withdrawal when trying to quit treatment. Now, a group of UK patients are suing GlaxoSmithKline for the same withdrawal problems, seeking up to $98,000 per patient, or $31 million-plus with the 314 patients participating so far. Of course, it's not simply the monetary damages that could hurt, but the attendant publicity, which might turn off potential patients
Hugh James dropped 97% clients who should contact SRA Fraud and Confidential Intelligence Bureau
Fraud and Confidential Intelligence Bureau is dedicated to gathering information and intelligence, operating in accordance with the National Intelligence Model.
http://www.sra.org.uk/solicitors/scams/fraud-dishonesty.page
http://www.sra.org.uk/solicitors/scams/fraud-dishonesty.page
BBC Panorama / Shelley Jofre KNOWINGLY put lives at risk to support Hugh James Seroxat only litigation
2.30 in Jofre says - ” read a little bit in news paper about patients complaints” year 2000 about ” Seroxat difficult to withdraw from” .. Jofre found it intriguing Jofre had only just started working on Panorama at that stage
3.30 in ” Jofre calls SSRI’s “SELECTIVE Serotonin Reuptake Inhibitors”
4.14 Jofre knew little of how the pharmcutical industry worked
4 .30 in Ed says - lets look at antidepressant story
4 45 Jofre says although problems with whole class of antidepressants we (bbc) decided to concentrate on Seroxat Why we narrowed down on Seroxat 1 because it was made by GSK 2 all the drugs in class cause suicidal thinking on dose change 3 Seroxat had a unique problem of withdrawal BECAUSE IT WAS LONGER ACTING … we decided to focus research into this drug
6.00 in - 40 min Panorama film took Shelley Jofre 8 months to make
6.10 in - It’s not something you do lightly WE WERE TAKING ON the worlds second largest drug company
7.30 We were talking to the lawyer the whole way through production
9.30 in - Jofre says “we took a punt” on Dr David Healy
Seroxat withdrawal freefall - how did they get off - expose legalaid fraud - all SSRI/SNRI not just Seroxat
www.ahrp.org/COI/PaxilDeclineUK.pdf -
Chart 5 demonstrates the immense value to Society of free and independent Public Service
Broadcasting and Internet communication. This combination has triggered the growth of
awareness of SSRI danger. It has united the many thousands of victims of SSRIs across the
world with some professionals who have laboured so long in a cause for saving lives, seeking justice and exposing dysfunctional drug regulation. Chart 5 shows that the tide has turned in the UK. Great encouragement should be taken from this life saving victory. However efforts must continue both to expose the known risks of paroxetine (Seroxat, Paxil) and all the other ill validated SSRIs and to call for the establishment an effective independent Drug Safety Regulator in every country, the absence of which is the root cause of this ongoing officially supported tragedy.
Graham Aldred 17 May 2004
Chart 5 demonstrates the immense value to Society of free and independent Public Service
Broadcasting and Internet communication. This combination has triggered the growth of
awareness of SSRI danger. It has united the many thousands of victims of SSRIs across the
world with some professionals who have laboured so long in a cause for saving lives, seeking justice and exposing dysfunctional drug regulation. Chart 5 shows that the tide has turned in the UK. Great encouragement should be taken from this life saving victory. However efforts must continue both to expose the known risks of paroxetine (Seroxat, Paxil) and all the other ill validated SSRIs and to call for the establishment an effective independent Drug Safety Regulator in every country, the absence of which is the root cause of this ongoing officially supported tragedy.
Graham Aldred 17 May 2004
Saturday, 16 October 2010
Fiddaman visitor statistics rigged - the evidence is clear
Fiddaman's page views rigged - most NOT interested in Seroxat
GSK NOT concerned about Seroxat sales - because millions easily withdrew
SSRI, SNRI - 2009 Annual Total Prescription Increases Hit Record High - 2.54 million
http://tuesday1st.blogspot.com/
Friday, 15 October 2010
Seroxat suit comprises only 314 clients © 2009 FierceMarkets
Seroxat TRUTH - suit comprises only 314 clients © 2009 FierceMarkets
Seroxat suit comprises only 314 clients © 2009 FierceMarkets
http://209.85.229.132/search?q=cache:HVY-Qp_p-YAJ:www.fiercepharma.com/story/uk-patients-sue-paxil-withdrawal/2008-01-09+harvey+seroxat&cd=14&hl=en&ct=clnk
Poor Paxil. It was the first antidepressant to be slapped with a suicide-risk warning. It's drawn fire--and lawsuits--from U.S. patients who say they went into withdrawal when trying to quit treatment. Now, a group of UK patients are suing GlaxoSmithKline for the same withdrawal problems, seeking up to $98,000 per patient, or $31 million-plus with the 314 patients participating so far. Of course, it's not simply the monetary damages that could hurt, but the attendant publicity, which might turn off potential patients.
Sold as Seroxat in the UK, the drug is "defective" under Britain's 1987 Consumer Protection Act--or so says the patients' attorney, Mark Harvey of the law firm Hugh James. A few of his clients have not been able to stop taking Seroxat because of their withdrawal symptoms, he says. When they began treatment, not only was there no warning of withdrawal problems on the drug's label, but it specifically stated that the drug was not addictive.
Harvey has been working on this suit since at least 2004, when it first became fashionable to sue Glaxo for Paxil/Seroxat-related woes. The drug was banned in the UK for kids under 18 in 2003; since then, lawsuits over paroxetine's side effects have flown on both sides of the Atlantic.Read more: http://209.85.229.132/search?q=cache:HVY-Qp_p-YAJ:www.fiercepharma.com/story/uk-patients-sue-paxil-withdrawal/2008-01-09+harvey+seroxat&cd=14&hl=en&ct=clnk
Seroxat suit comprises only 314 clients © 2009 FierceMarkets
http://209.85.229.132/search?q=cache:HVY-Qp_p-YAJ:www.fiercepharma.com/story/uk-patients-sue-paxil-withdrawal/2008-01-09+harvey+seroxat&cd=14&hl=en&ct=clnk
Poor Paxil. It was the first antidepressant to be slapped with a suicide-risk warning. It's drawn fire--and lawsuits--from U.S. patients who say they went into withdrawal when trying to quit treatment. Now, a group of UK patients are suing GlaxoSmithKline for the same withdrawal problems, seeking up to $98,000 per patient, or $31 million-plus with the 314 patients participating so far. Of course, it's not simply the monetary damages that could hurt, but the attendant publicity, which might turn off potential patients.
Sold as Seroxat in the UK, the drug is "defective" under Britain's 1987 Consumer Protection Act--or so says the patients' attorney, Mark Harvey of the law firm Hugh James. A few of his clients have not been able to stop taking Seroxat because of their withdrawal symptoms, he says. When they began treatment, not only was there no warning of withdrawal problems on the drug's label, but it specifically stated that the drug was not addictive.
Harvey has been working on this suit since at least 2004, when it first became fashionable to sue Glaxo for Paxil/Seroxat-related woes. The drug was banned in the UK for kids under 18 in 2003; since then, lawsuits over paroxetine's side effects have flown on both sides of the Atlantic.Read more: http://209.85.229.132/search?q=cache:HVY-Qp_p-YAJ:www.fiercepharma.com/story/uk-patients-sue-paxil-withdrawal/2008-01-09+harvey+seroxat&cd=14&hl=en&ct=clnk
"are the press looking for seroxat clients" - top keyword search
October 15, 2010
PM Google are the press looking for seroxat clients
http://bobfiddaman.blogspot.com/2010/10/media-publicity-impact-on-prescribing.html
PM Google are the press looking for seroxat clients
http://bobfiddaman.blogspot.com/2010/10/media-publicity-impact-on-prescribing.html
GlaxoSmithKline's Lawyers - UK SEROXAT LITIGATION AND THE UK PRESS.- most viewed post
When I tapered off Paxil I used an oral syringe. I 'came down' by half a mg per week and it took me 18 months to taper down from 40mg per day to 22mg per day. That is NOT a discontinuation, that IS a withdrawal. Paxil IS addictive, there are thousands of stories of people suffering because they cannot taper off this drug.
After 18 months I went cold turkey. It took me 3 months to get passed the zaps, profuse sweating, anger outbursts, suicidal thoughts, craving (temptation to go back on Paxil) plus a whole host of other side effects.
There are over 10,000 stories online from patients who have suffered withdrawal symptoms at the hands of Paxil. To suggest that antidepressants are not addictive is basically sticking your middle finger up to those that have... and still are suffering trying to taper off this drug.
http://neighbors.denverpost.com/viewtopic.php?f=16&t=9437847&p=221585
After 18 months I went cold turkey. It took me 3 months to get passed the zaps, profuse sweating, anger outbursts, suicidal thoughts, craving (temptation to go back on Paxil) plus a whole host of other side effects.
There are over 10,000 stories online from patients who have suffered withdrawal symptoms at the hands of Paxil. To suggest that antidepressants are not addictive is basically sticking your middle finger up to those that have... and still are suffering trying to taper off this drug.
http://neighbors.denverpost.com/viewtopic.php?f=16&t=9437847&p=221585
Thursday, 14 October 2010
Seroxat - Paxil protest photographs of Rob Robinson's non event
Seroxat/Paxil - sales in freefall HOW DID THEY WITHDRAW?
Seroxat Panorama watched by 4.4 million - produced only 1,374 e-mails !
An estimated 4.4m people recently watched “Secrets of Seroxat” (Panorama, BBC-TV), a 50-minute programme about paroxetine, an SSRI antidepressant for which UK general practitioners wrote an estimated 4.7m prescriptions in 2001. The programme attracted a record response, including some 65,000 telephone calls, 124,000 website hits, and 1,374 emails.We systematically analysed the contents of these emails, and in this paper consider how they might help clinicians and their patients, as well as providing an indispensable element in pharmacovigilance and post-marketing drug surveillance.
http://www.motkur.no/paroxetine.pdf
from
Paroxetine, Panorama and user reporting of
ADRs: Consumer intelligence matters in
clinical practice and post-marketing drug
surveillance
Charles Medawar a,∗, Andrew Herxheimer b, Andrew Bell c and Shelley Jofre c
a Social Audit Ltd., London, UK
bDIPEx Project, Department of Primary Health Care, University of Oxford, Oxford, UK
c British Broadcasting Corporation (BBC), London, UK
http://www.motkur.no/paroxetine.pdf
from
Paroxetine, Panorama and user reporting of
ADRs: Consumer intelligence matters in
clinical practice and post-marketing drug
surveillance
Charles Medawar a,∗, Andrew Herxheimer b, Andrew Bell c and Shelley Jofre c
a Social Audit Ltd., London, UK
bDIPEx Project, Department of Primary Health Care, University of Oxford, Oxford, UK
c British Broadcasting Corporation (BBC), London, UK
Seroxat yellow cards rose by 61% after Panorama - yeah made their own!
Seroxat yellow cards rose by 61% after Panorama - yeah made their own!
http://groups.yahoo.com/group/uksurvivors/message/46433
extract - from Seroxat NewsletterBBC Panorama is planning to broadcast a follow up to the `Secrets of Seroxat' documentary in May. Many of you who contacted the programme will have been asked by the producer to fill in a special version of the Yellow Card designed for Panorama by MIND. The Yellow Card system is used by GPs to report drug safety issues to the Medicine's Control Agency. If your GP has not already filled in a Yellow Card about Seroxat, please ask them to do so.see full document here
http://www.seroxatusergroup.org.UK/Documents/newsletter2.doc
http://groups.yahoo.com/group/uksurvivors/message/46433
extract - from Seroxat NewsletterBBC Panorama is planning to broadcast a follow up to the `Secrets of Seroxat' documentary in May. Many of you who contacted the programme will have been asked by the producer to fill in a special version of the Yellow Card designed for Panorama by MIND. The Yellow Card system is used by GPs to report drug safety issues to the Medicine's Control Agency. If your GP has not already filled in a Yellow Card about Seroxat, please ask them to do so.see full document here
http://www.seroxatusergroup.org.UK/Documents/newsletter2.doc
media publicity impact on prescribing of paroxetine and the notification of suspected adverse drug reactions
Br J Clin Pharmacol. 2006 February; 61(2): 224–228.
Published online 2005 October 27. doi: 10.1111/j.1365-2125.2005.02527.x. PMCID: PMC1884992
Copyright © 2005 Blackwell Publishing Ltd
Did intense adverse media publicity impact on prescribing of paroxetine and the notification of suspected adverse drug reactions? Analysis of routine databases, 2001–2004
Richard M Martin, Margaret May, and David Gunnell
Department of Social Medicine, University of Bristol, Bristol, UK
Correspondence Richard Martin, Department of Social Medicine, University of Bristol, Canynge Hall, Whiteladies Road, Bristol BS8 2PR, UK. Tel: + 117 928 7321 Fax: + 117 928 7236 E-mail: Email: richard.martin@bristol.ac.uk
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884992/
Figure 2
Suspected adverse drug reactions to paroxetine (yellow-card reports) per 100 000 paroxetine prescriptions by year and month between 2001 and 2004. Arrows indicate dates of Panorama programmes (solid arrows) or regulatory communications (dashed arrows)
Analysis of yellow-card data suggests that adverse publicity, particularly the three Panorama programmes, was associated with marked, short-term peaks in reporting (Figure 2). The mean rate of yellow-card reporting (per 100 000 prescriptions) in the month before each regulatory announcement was 7.6 vs. 8.0 in the month after. In contrast, the mean rate of yellow-card reporting in the month before each media publicity episode was 8.3 vs. 13.4 in the month after. An identical pattern of peaks and troughs in yellow-card reporting of suspected adverse drug reactions to paroxetine was observed when the temporal trend in number of reports was plotted (data not shown).
From:Br J Clin Pharmacol. 2006 February; 61(2): 224–228.
Published online 2005 October 27. doi: 10.1111/j.1365-2125.2005.02527.x.Copyright © 2005 Blackwell Publishing Ltd
Published online 2005 October 27. doi: 10.1111/j.1365-2125.2005.02527.x. PMCID: PMC1884992
Copyright © 2005 Blackwell Publishing Ltd
Did intense adverse media publicity impact on prescribing of paroxetine and the notification of suspected adverse drug reactions? Analysis of routine databases, 2001–2004
Richard M Martin, Margaret May, and David Gunnell
Department of Social Medicine, University of Bristol, Bristol, UK
Correspondence Richard Martin, Department of Social Medicine, University of Bristol, Canynge Hall, Whiteladies Road, Bristol BS8 2PR, UK. Tel: + 117 928 7321 Fax: + 117 928 7236 E-mail: Email: richard.martin@bristol.ac.uk
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884992/
Figure 2
Suspected adverse drug reactions to paroxetine (yellow-card reports) per 100 000 paroxetine prescriptions by year and month between 2001 and 2004. Arrows indicate dates of Panorama programmes (solid arrows) or regulatory communications (dashed arrows)
Analysis of yellow-card data suggests that adverse publicity, particularly the three Panorama programmes, was associated with marked, short-term peaks in reporting (Figure 2). The mean rate of yellow-card reporting (per 100 000 prescriptions) in the month before each regulatory announcement was 7.6 vs. 8.0 in the month after. In contrast, the mean rate of yellow-card reporting in the month before each media publicity episode was 8.3 vs. 13.4 in the month after. An identical pattern of peaks and troughs in yellow-card reporting of suspected adverse drug reactions to paroxetine was observed when the temporal trend in number of reports was plotted (data not shown).
From:Br J Clin Pharmacol. 2006 February; 61(2): 224–228.
Published online 2005 October 27. doi: 10.1111/j.1365-2125.2005.02527.x.Copyright © 2005 Blackwell Publishing Ltd
Seroxat consumption massive decline - how did the manage to withdraw?
Wednesday, 13 October 2010
Solicitors Regulation Authority - Fraud and Confidential Intelligence Bureau
http://www.sra.org.uk/solicitors/scams/fraud-dishonesty.page
Our Fraud and Confidential Intelligence Bureau is dedicated to gathering information and intelligence, operating in accordance with the National Intelligence Model.
If you know, or suspect, that another regulated person, or their employee, is involved in dishonest or serious misconduct, contact our Red Alert line on 0845 850 0999 or 01926 439673 or email redalert@sra.org.uk. Red Alert is available to all members of the profession and their staff who want to report concerns.
Any report you make is treated with strict confidentiality.
Our Fraud and Confidential Intelligence Bureau is dedicated to gathering information and intelligence, operating in accordance with the National Intelligence Model.
If you know, or suspect, that another regulated person, or their employee, is involved in dishonest or serious misconduct, contact our Red Alert line on 0845 850 0999 or 01926 439673 or email redalert@sra.org.uk. Red Alert is available to all members of the profession and their staff who want to report concerns.
Any report you make is treated with strict confidentiality.
Subscribe to:
Posts (Atom)











